Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    Morphic Holding, Inc. (MORF)

    Price:

    56.99 USD

    ( + 0.02 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    MORF
    Name
    Morphic Holding, Inc.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    56.990
    Market Cap
    2.862B
    Enterprise value
    1.168B
    Currency
    USD
    Ceo
    Praveen P. Tipirneni
    Full Time Employees
    128
    Ipo Date
    2019-06-27
    City
    Waltham
    Address
    35 Gatehouse Drive, A2

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Regeneron Pharmaceuticals, Inc.

    VALUE SCORE:

    6

    Symbol
    REGN
    Market Cap
    59.118B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    Harmony Biosciences Holdings, Inc.

    VALUE SCORE:

    12

    Symbol
    HRMY
    Market Cap
    1.549B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Agios Pharmaceuticals, Inc.

    VALUE SCORE:

    12

    Symbol
    AGIO
    Market Cap
    2.456B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -27.751
    P/S
    0
    P/B
    4.616
    Debt/Equity
    0.005
    EV/FCF
    -35.440
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    0
    Earnings yield
    -0.036
    Debt/assets
    0.005
    FUNDAMENTALS
    Net debt/ebidta
    0.401
    Interest coverage
    0
    Research And Developement To Revenue
    0
    Intangile to total assets
    0
    Capex to operating cash flow
    -0.012
    Capex to revenue
    0
    Capex to depreciation
    1.704
    Return on tangible assets
    -0.159
    Debt to market cap
    0.001
    Piotroski Score
    2.000
    FUNDAMENTALS
    PEG
    4.078
    P/CF
    -36.379
    P/FCF
    -36.037
    RoA %
    -15.923
    RoIC %
    -19.173
    Gross Profit Margin %
    0
    Quick Ratio
    24.127
    Current Ratio
    24.127
    Net Profit Margin %
    0
    Net-Net
    11.991
    FUNDAMENTALS PER SHARE
    FCF per share
    -1.585
    Revenue per share
    0
    Net income per share
    -2.054
    Operating cash flow per share
    -1.567
    Free cash flow per share
    -1.585
    Cash per share
    12.543
    Book value per share
    12.345
    Tangible book value per share
    12.345
    Shareholders equity per share
    12.345
    Interest debt per share
    0.066
    TECHNICAL
    52 weeks high
    57.000
    52 weeks low
    19.345
    Current trading session High
    57.000
    Current trading session Low
    56.970
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -26.267
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -15.564
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -5.213
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -7.205
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    35.111
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -18.426
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.462
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -1.502
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    33.244
    DESCRIPTION

    Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

    NEWS
    https://images.financialmodelingprep.com/news/lilly-completes-acquisition-of-morphic-to-improve-outcomes-and-expand-20240816.jpg
    Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

    prnewswire.com

    2024-08-16 08:38:00

    Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057 Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology INDIANAPOLIS , Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases, including a selective oral small molecule inhibitor of α4β7 integrin (known as MORF-057) for inflammatory bowel disease (IBD).

    https://images.financialmodelingprep.com/news/eli-lilly-stock-finishes-lower-after-news-of-bond-20240812.jpg
    Eli Lilly Stock Finishes Lower After News of Bond Sale to Fund Morphic Deal

    investopedia.com

    2024-08-12 18:01:19

    Eli Lilly (LLY) shares finished Monday lower after a back-and-forth session in which an analyst upgrade sent them higher before news of $5 billion in bond sales pulled them into the red.

    https://images.financialmodelingprep.com/news/morf-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-20240811.jpg
    MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Clients to Contact the Firm!

    accesswire.com

    2024-08-11 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-an-20240809.jpg
    MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm Today!

    accesswire.com

    2024-08-09 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE:LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/calling-all-morphic-holding-inc-morf-investors-contact-bronstein-gewirtz-20240808.jpg
    Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

    globenewswire.com

    2024-08-08 16:00:00

    NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (“Morphic”) (NASDAQ: MORF) and Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-20240808.jpg
    MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm Today!

    accesswire.com

    2024-08-08 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-stockholder-alert-bronstein-gewirtz-and-grossman-llc-announces-20240807.jpg
    MORF STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!

    accesswire.com

    2024-08-07 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-an-20240806.jpg
    MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!

    accesswire.com

    2024-08-06 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-20240805.jpg
    MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm Today!

    accesswire.com

    2024-08-05 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-20240804.jpg
    MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Stockholders to Contact the Firm!

    accesswire.com

    2024-08-04 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/calling-all-morphic-holding-inc-morf-investors-contact-bronstein-20240802.jpg
    Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

    globenewswire.com

    2024-08-02 16:00:00

    NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (“Morphic”) (NASDAQ: MORF) and Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-20240802.jpg
    MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Stockholders to Contact the Firm!

    accesswire.com

    2024-08-02 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-stockholder-alert-bronstein-gewirtz-and-grossman-llc-announces-20240801.jpg
    MORF STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm!

    accesswire.com

    2024-08-01 10:00:00

    NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-20240731.jpg
    MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm!

    accesswire.com

    2024-07-31 10:00:00

    NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.

    https://images.financialmodelingprep.com/news/morf-alert-wohl-fruchter-llp-files-class-action-lawsuit-20240731.jpg
    MORF Alert: Wohl & Fruchter LLP Files Class Action Lawsuit on Behalf of Shareholders of Morphic Holding, Inc., in the U.S. District Court for the Northern District of California

    globenewswire.com

    2024-07-31 09:15:00

    MONSEY, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Wohl & Fruchter LLP announces that on July 25, 2024, it filed a class action lawsuit in the United States District Court for the Northern District of California, captioned Zappia v.

    https://images.financialmodelingprep.com/news/morf-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-20240730.jpg
    MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Shareholders to Contact the Firm!

    accesswire.com

    2024-07-30 10:00:00

    NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.